<DOC>
	<DOCNO>NCT02497612</DOCNO>
	<brief_summary>Primary Objective : To determine whether single dose combination OZ439 ( Artefenomel ) /FQ ( Ferroquine ) efficacious treatment uncomplicated Plasmodium falciparum malaria adult child . Secondary Objectives : To evaluate efficacy OZ439 ( Artefenomel ) /FQ ( Ferroquine ) : - To determine incidence recrudescence re-infection . - To determine time relief fever parasite clearance . To evaluate safety tolerability OZ439 ( Artefenomel ) /FQ ( Ferroquine ) . To evaluate pharmacokinetics OZ439 ( Artefenomel ) /FQ ( Ferroquine ) . To explore vitro drug resistance P. falciparum infect patient &gt; 14 year old Vietnamese site .</brief_summary>
	<brief_title>To Evaluate Efficacy Single Dose Regimen Ferroquine Artefenomel Adults Children With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
	<detailed_description>Total duration 67 day patient .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<criteria>Inclusion criterion : Male female patient age &gt; 6 month old &lt; 70 year old : Cohort 1 = 14 year &lt; age &lt; 70 year body weight ≥35 kg . Cohort 2 = 5 year &lt; age ≤14 year . Cohort 3 = 2 year &lt; age ≤5 year . Cohort 4 = 6 month &lt; age ≤2 year . Body weight ≥5 kg ≤90 kg . Presence monoinfection P. falciparum : Fever , define axillary temperature ≥37.5 C oral/rectal/tympanic temperature ≥38 C , history fever previous 24 hour ( history fever must document ) , Microscopically ( blood smear ) confirm parasite infection , range 1000 100 000 asexual parasites/µL blood . Informed Consent Form sign patient legally acceptable representative minor patient . Exclusion criterion : Presence severe malaria . Antimalarial treatment : With piperaquinebased compound , mefloquine , naphthoquine sulphadoxine/pyrimethamine ( SP ) within previous 6 week ( inhibition new infection fall 50 % ) . With amodiaquine chloroquine within previous 4 week . With quinine , halofantrine , lumefantrinebased compound antimalarial treatment antibiotic antimalarial activity ( include cotrimoxazole , tetracycline , quinolones fluoroquinolones , azithromycin ) within past 14 day . With herbal product traditional medicine , within past 7 day . Known history evidence clinically significant disorder . Previous treatment within 5 time halflife within last 14 day , whichever long : Pgp substrate , CYP2D6 main substrate and/or strong CYP2C CYP3A inhibitor and/or moderate inhibitor inhibit CYP2C CYP3A and/or CYP inducer . Mixed plasmodium infection . Severe vomit . Severe malnutrition . Laboratory parameter clinical significant abnormality and/or reach critical value . For Liver Function Test . Aspartate transferase [ AST &gt; 2 ULN ] , alanine transferase [ ALT &gt; 2 ULN ] total bilirubin &gt; 1.5 ULN . Presence Hepatitis A Immunoglobulin M ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) . Have receive investigational drug within past 4 week . Previous participation malaria vaccine study receive malaria vaccine circumstance . Measles yellow fever vaccine injection within last 15 day plan 28 day randomization . Female patient child bear potential willing use effective contraceptive ( ) method ( ) duration study . Positive serum urine betahuman chorionic gonadotropin ( ßHCG ) pregnancy study screen female participant childbearing potential . Breastfeeding woman . Male patient partner child bear potential willing use effective method birth control study treatment period . Splenectomized patient presence surgical scar leave hypochondrium . Patient unable drink . Known history hypersensitivity , allergic adverse reaction ferroquine aminoquinolones OZ439 OZ277 . Family history sudden death congenital prolongation QTc interval know congenital prolongation QTcinterval clinical condition know prolong QTc interval e.g. , patient history symptomatic cardiac arrhythmia clinically relevant bradycardia . QTcF &gt; 450 m screening . Hypokalemia ( &lt; 3.5 mmol/L ) , hypocalcemia ( &lt; 2.0 mmol/L ) hypomagnesemia ( &lt; 0.5 mmol/L ) screening . Any treatment know induce lengthen QT interval . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>